A Small Story That Shows How HPV Vaccines Work

A young woman walks into the office with a lesion on the dorsum of the tongue. A papilloma.

Her GP sent her. She asks if I can remove it.

Before any scalpel talk I ask about HPV vaccination. She had started the series a year earlier and stopped after the first dose. She never received the rest. The schedule needs more than one shot, spaced over months: without boosters, immune memory stays thin.

I tell her to finish the series before any excision. Concrete reason: if I cut that lesion out while her immune system still reads HPV poorly, the lesion can return. Or others can form.

She agrees. She gets the second dose.

Two days later

I did not expect that response.

Prophylactic vaccines mostly work upstream: they block infection before a lesion starts. Two days later, though, the papilloma is much smaller. She feels a local burn.

At seven days the lesion is gone. No scalpel. No laser. Just a vaccine booster and an immune response that did the work.

What may have happened

HPV lives in epithelial cells and stays off the immune radar for a long time. The booster likely reopened a response already primed by dose one: rising antibodies and cytotoxic CD8+ T cells hunting infected cells in peripheral tissue.

Locally, interferons and pro-inflammatory cytokines climb. A small mass does not vanish in 24–48 hours by slow phagocytosis. Acute collapse of the microcapillaries feeding the papilloma is more plausible. Without blood, the lesion shrinks and necrotises. The burn she reported fits that phase.

What 2024–2026 literature says

Prevention is solid. Bergman and colleagues, in the 2025 Cochrane network meta-analysis (60 trials, 157,414 participants), show that WHO-prequalified HPV vaccines cut vaccine-type CIN2+ (RR 0.40 at six years in women aged 15–25) and anogenital warts (RR 0.38; about 25 fewer cases per 1,000 vaccinated). Follow-up is still too short for invasive cancers: no events counted, and no safety signal on serious adverse events (RR 0.99).

Clearing lesions that already exist is a different chapter. Leeyaphan and colleagues (2025) pooled individual data from 183 patients with recalcitrant warts treated with intramuscular HPV vaccine: complete resolution in 61.2%, median 24 weeks, from uncontrolled studies with high risk of bias. Villemure and Wilby (2024), reviewing active anogenital warts, conclude the vaccine may offer therapeutic benefit, yet evidence quality stays low. In plain terms: my case sits in a real but thin strip of the literature—possible, not predictable, not the rule.

For the mouth the epidemiology is clearer. Maltseva and colleagues (BMC Cancer, 2025) summarise that oral HPV DNA appears in 1–12% of the general population, more often in males and in people living with HIV; HPV16 dominates. The same review: prophylactic vaccination links to fewer oral infections with vaccine types. Mak and colleagues (Vaccine, 2026) add a chairside piece: patients are often comfortable discussing HPV and vaccination in dental settings (23–86% across studies), yet most never get that conversation during a visit. The dental office remains an underused contact point for mouth–body prevention.

Prevention is still the real job

With HPV we are talking benign papillomas, precancerous lesions, and cancers of the oral cavity, oropharynx, larynx, penis, and cervix. Finishing the series covers the most oncogenic types even after prior infection: the vaccine does not “cure” every lesion, but it closes coverage gaps and strengthens memory.

This young woman now has trained immunity. The lesion is gone. She also has protection ahead—against new infections, against progression of latent ones, against more serious lesions.

We treat people, not just patches of mucosa.

Vaccinate your kids

In Italy HPV vaccination is recommended and free from age 11. Active offer continues at least to age 18 for males and 26 for females, with regional extensions.

Book here: https://infohpv.it/prenotare-la-vaccinazione/